Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have received an average recommendation of “Hold” from the seven research firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $31.00.
Several brokerages recently weighed in on ITCI. ValuEngine upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. BidaskClub upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Friday, April 26th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $26.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, May 8th.
NASDAQ:ITCI traded up $1.66 during mid-day trading on Monday, hitting $14.17. The stock had a trading volume of 697,483 shares, compared to its average volume of 371,987. The stock has a market capitalization of $689.55 million, a PE ratio of -4.99 and a beta of 1.34. The stock’s 50 day moving average is $12.80. Intra-Cellular Therapies has a 52 week low of $10.21 and a 52 week high of $23.62. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.59 and a quick ratio of 9.59.
In related news, Director Christopher D. Alafi bought 170,000 shares of the stock in a transaction on Wednesday, June 12th. The shares were purchased at an average price of $11.73 per share, with a total value of $1,994,100.00. Following the purchase, the director now owns 750,106 shares in the company, valued at $8,798,743.38. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher D. Alafi bought 100,000 shares of the stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $12.56 per share, for a total transaction of $1,256,000.00. Following the purchase, the director now owns 750,106 shares in the company, valued at approximately $9,421,331.36. The disclosure for this purchase can be found here. 17.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its stake in Intra-Cellular Therapies by 0.7% during the 1st quarter. FMR LLC now owns 8,267,510 shares of the biopharmaceutical company’s stock valued at $100,698,000 after buying an additional 58,561 shares during the period. BlackRock Inc. grew its stake in shares of Intra-Cellular Therapies by 1.9% in the 4th quarter. BlackRock Inc. now owns 4,004,666 shares of the biopharmaceutical company’s stock worth $45,614,000 after purchasing an additional 76,356 shares during the last quarter. Wasatch Advisors Inc. grew its stake in shares of Intra-Cellular Therapies by 19.0% in the 1st quarter. Wasatch Advisors Inc. now owns 2,361,619 shares of the biopharmaceutical company’s stock worth $28,765,000 after purchasing an additional 377,561 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Intra-Cellular Therapies by 1.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,444,223 shares of the biopharmaceutical company’s stock worth $16,450,000 after purchasing an additional 24,335 shares during the last quarter. Finally, Samlyn Capital LLC grew its stake in shares of Intra-Cellular Therapies by 64.2% in the 4th quarter. Samlyn Capital LLC now owns 1,266,138 shares of the biopharmaceutical company’s stock worth $14,421,000 after purchasing an additional 494,918 shares during the last quarter. 69.15% of the stock is currently owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Further Reading: What is the Beige Book?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.